Physician profile
David Jonathan Sands
NPI 1548265788
$1,046.43
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $57.88 · 2021: $78.16 · 2022: $212 · 2023: $49.48 · 2024: $180 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $189.38 | 2019-2021 | |
| Nevro Corp. | $180.30 | 2024 | Senza |
| Acorda Therapeutics, INC | $142.07 | 2021-2023 | Inbrija |
| Amgen INC. | $136.70 | 2025 | Krystexxa |
| Amneal Pharmaceuticals LLC | $102.75 | 2019-2020 | |
| Abbvie INC. | $77.79 | 2022 | |
| Lundbeck LLC | $46.45 | 2019 | |
| Orthofix Medical, INC. | $34.21 | 2023 | Spinal-Stim, Physio-Stim |
| Tei Medical INC. | $29.78 | 2019 | |
| Djo, LLC | $28.22 | 2025 | Cmf |
| Avion Pharmaceuticals | $24.28 | 2022 | |
| Vertical Pharmaceuticals, LLC | $21.45 | 2019 | |
| Hikma Pharmaceuticals USA | $18.00 | 2019 | |
| Organogenesis INC. | $15.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.